Orthocell recorded first use of Remplir™ in the US overnight, which is an important step in establishing surgical experience and knowledge of the product.
The Company’s US distributor network now includes 14 specialist nerve distributors with mature, direct-to-surgeon, hospital and other customer relationships across 25 US states.
Orthocell CEO and MD, Paul Anderson, said:
“This first US surgery is a significant milestone for Orthocell and the roll out of Remplir in the US. It signals the start of our commercial journey in the world’s largest healthcare and nerve repair markets, and reflects our commitment to delivering innovative, clinically proven solutions to surgeons and their patients.”
An investor webinar will be held at 10:00am AWST | 12:00pm AEST on Wednesday 2 July 2025 to provide insight into this milestone achievement.